Exercise program to prevent nerve damage from chemotherapy in breast cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to determine if a therapeutic exercise program combined with blood flow restriction (BFR) can prevent chemotherapy-induced peripheral neuropathy (CIPN) in patients undergoing neoadjuvant chemotherapy for HER2+ breast cancer. Participants will engage in the PRESIONA exercise program, which is designed to protect nerve fibers from the neurotoxic effects of chemotherapy. The study compares the outcomes of this exercise intervention against usual care to assess its effectiveness in preventing CIPN.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years or older
* HER2+ breast cancer diagnosis
* On the waiting list to anticancer medical treatment (taxanes-based neoadjuvant chemotherapy)

Exclusion Criteria:

* Previous diagnosis of cancer
* Pregnant
* Cardiac pathology
* No symptoms or pathology that could be confused with neuropathy or related to diabetes
* No recommendation from oncologist for therapeutic exercise practice

Where it's running

• University of Granada
  Granada, Spain Recruiting

Study contacts

• Principal investigator: Irene Cantarero-Villanueva, PhD — Physical Therapy Deparment, Faculty of Health Sciences, University of Granada
• Study coordinator: Irene Cantarero-Villanueva, PhD
• Email: irenecantarero@ugr.es
• Phone: 958248764

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-powered mobile app to support chemotherapy for breast cancer

  A mobile app in Arabic uses AI to help women undergoing chemotherapy see if it can improve symptom control and medication adherence compared with standard care.

  Recruiting University of Baghdad · Baghdad · NCT07273812

• Cryoablation for small breast tumors (SIX)

  This study will test whether cryoablation works as well as standard breast surgery for people with small (≤2.0 cm), unifocal early-stage breast cancer and will compare direct costs over one year.

  Recruiting Phase 3 Hospital do Coracao · São Paulo, São Paulo and 1 other locations · NCT06839001

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

• Blood test to identify patients at high risk for breast cancer

  This study is testing a new blood test that uses advanced technology to see if it can help identify women at high risk for breast cancer.

  Recruiting at 2 sites EXoPERT · Honolulu, Hawaii and 2 other locations · NCT06672302

• HydroMARK Plus versus HydroMARK: comparing biopsy site marker retrieval and surgeon satisfaction

  This trial will test whether the HydroMARK Plus breast biopsy marker is retrieved more successfully than the current HydroMARK and whether surgeons are more satisfied with its removal for patients having biopsy clips removed during surgery.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT06294574

• Using tart cherry juice to prevent nerve damage from chemotherapy in breast cancer patients

  This study is testing if drinking tart cherry juice can help prevent nerve damage in breast cancer patients receiving chemotherapy.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06268665

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.